Stock Track | United Therapeutics Plunges 7.46% in Pre-market After Q2 Revenue Misses Estimates

Stock Track

Aug 05

United Therapeutics (UTHR) shares tumbled 7.46% in pre-market trading on Wednesday after the company reported second-quarter 2026 revenue that fell short of Wall Street expectations.

The biotech company posted quarterly revenue of $783.3 million, missing the consensus estimate of $805.6 million, according to IBES data from Refinitiv. Net income for the quarter came in at $333 million, with earnings per share of $7.27.

The revenue miss appeared to overshadow the company's earnings performance, triggering a sharp sell-off in pre-market action as investors reacted to the shortfall against analyst projections.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1161280333"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161280333\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161280333?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 18:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161280333","market":"us","top_or_hot":-1,"title":"Stock Track | United Therapeutics Plunges 7.46% in Pre-market After Q2 Revenue Misses Estimates","media":"Stock Track","content":"<p>United Therapeutics (UTHR) shares tumbled 7.46% in pre-market trading on Wednesday after the company reported second-quarter 2026 revenue that fell short of Wall Street expectations.</p><p>The biotech company posted quarterly revenue of $783.3 million, missing the consensus estimate of $805.6 million, according to IBES data from Refinitiv. Net income for the quarter came in at $333 million, with earnings per share of $7.27.</p><p>The revenue miss appeared to overshadow the company's earnings performance, triggering a sharp sell-off in pre-market action as investors reacted to the shortfall against analyst projections.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | United Therapeutics Plunges 7.46% in Pre-market After Q2 Revenue Misses Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | United Therapeutics Plunges 7.46% in Pre-market After Q2 Revenue Misses Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-05 18:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>United Therapeutics (UTHR) shares tumbled 7.46% in pre-market trading on Wednesday after the company reported second-quarter 2026 revenue that fell short of Wall Street expectations.</p><p>The biotech company posted quarterly revenue of $783.3 million, missing the consensus estimate of $805.6 million, according to IBES data from Refinitiv. Net income for the quarter came in at $333 million, with earnings per share of $7.27.</p><p>The revenue miss appeared to overshadow the company's earnings performance, triggering a sharp sell-off in pre-market action as investors reacted to the shortfall against analyst projections.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UTHR","symbol_name":"美国联合医疗","start_time":0,"source_url":"","article_id":"1161280333","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161280333","pubTimestamp":1785926172,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"United Therapeutics (UTHR) shares tumbled 7.46% in pre-market trading on Wednesday after the company reported second-quarter 2026 revenue that fell short of Wall Street expectations.The biotech...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"UTHR":"美国联合医疗"},"translate_title":"股票跟踪 | United Therapeutics 第二季度收入未达预期后盘前暴跌 7.46%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1},"content_text":"United Therapeutics (UTHR) shares tumbled 7.46% in pre-market trading on Wednesday after the company reported second-quarter 2026 revenue that fell short of Wall Street expectations.The biotech company posted quarterly revenue of $783.3 million, missing the consensus estimate of $805.6 million, according to IBES data from Refinitiv. Net income for the quarter came in at $333 million, with earnings per share of $7.27.The revenue miss appeared to overshadow the company's earnings performance, triggering a sharp sell-off in pre-market action as investors reacted to the shortfall against analyst projections.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}